Effectiveness of Favipiravir monotherapy in the treatment of COVID-19: real world data analysis from Thailand

BACKGROUND: Previous studies showed that Favipiravir, a selective viral ribonucleic acid dependent-ribonucleic acid polymerase inhibitor, exhibited a trend of clinical improvement within 14 days and promoted viral clearance by day 7, without reduction of mortality rate in COVID-19. METHODS: During t...

Descripción completa

Detalles Bibliográficos
Autores principales: Srisubat, Attasit, Thanasitthichai, Somchai, Kongsaengdao, Subsai, Maneeton, Narong, Maneeton, Benchalak, Akksilp, Somsak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902286/
https://www.ncbi.nlm.nih.gov/pubmed/36776761
http://dx.doi.org/10.1016/j.lansea.2023.100166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902286/
https://www.ncbi.nlm.nih.gov/pubmed/36776761
http://dx.doi.org/10.1016/j.lansea.2023.100166

Ejemplares similares